Impact of practice changes on an antiretroviral budget in an HIV care program

Disease Management and Health Outcomes

Volumn 13, Issue 3, 2005, Pages 209-217

  Krentz, Hartmut B ^a,b,c   Gill, M John ^a,b  

^a Southern Alberta HIV Clinic   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c Southern Alberta Clinic   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; BUDGET; CANADA; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; DRUG COST; DRUG USE; FEMALE; HEALTH CARE; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MONITORING; PREDICTION; SOCIAL ASPECT;

EID: 22244475456     PISSN: 11738790     EISSN: 11738790     Source Type: Journal    
DOI: 10.2165/00115677-200513030-00006     Document Type: Article

References (40)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60
2. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA 1997; 277: 1962-9
3. Hogg, RS, Heath KV, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998; 279: 450-4
4. Ho DD. Time to hit HIV, early and hard. NEJM 1995; 333: 450-1
5. McDonald CK, Kuritzkes DR. Human immunodeficiency virus type 1 protease inhibitors. Arch Intern Med 1997; 157 (9): 951-9
6. Pakyz A, Israel D. Overview of protease inhibitors. J of Amer Pharm Assn 1997; NS37 (5): 543-51
7. Katlama C. Review of NNRTI's: 'today and tomorrow'. Int J Clin Pract 1999; Suppl. 103: 16-20
8. Arribas J. Comparison of NNRTIs in antiretroviral-naive patients. Int J STD AIDS 2001; 12 Suppl. 4: 3-9
9. Deeks SG. Determinants of virological response to antiretroviral therapy. Clin Infect Dis 2000; 30 Suppl. 2: S177-84
10. Miller LG, Hays RD. Measuring adherence to antiretroviral medication in clinical trials. HIV Clinical Trials 2000; 1 (1): 36-46
11. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000; 30 Suppl. 2: S171-6
12. Chesney MA, Ickovics J, Hecht FM, et al. Adherence: a necessity for successful HIV combination therapy. AIDS 1999; 13 Suppl. A: S271-8
13. Rutherford GW, Feldman KA, Kennedy GE. Three- or four versus two-drug antiretroviral maintenance regimens for HIV infection. Cochrane Database Syst Rev 2000; (2): CD002037
14. Hermans P. Current review and clinical management of patients with primary HIV-1 infection: limits and perspectives. Biomed Pharmacother 2001; 55 (6): 301-7
15. MacArthur RD. Antiretroviral therapy. Sequencing antiretrovirals. AIDS Read; 10 (6): 359-64
16. Goldscmidt RH, Balano KB, Legg JJ, et al. Individualized strategies in the ear of combination antiretroviral therapy. J Am Board Fam Pract 1998; (2): 158-65
17. Siliciano RF. Latency and reservoirs for HIV-1. AIDS 1999; 13 Suppl. A: S49-58
18. Siliciano JD, Siliciano RF. Latency and viral persistence in HIV-1 infection. J Clin Invest 2000; 106 (7): 839-45
19. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5: 512-17
20. Dybul M, Fauci AS, Barlett JC, et al. Guidelines for using antiretrovial agents among HIV-infected adults and adolescents. Ann Int Med 2002; 137 (5): 381-433
21. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002, 35
22. Eggar M, May M, Chene G, et al. Prognosis of HIV-infected patients starting highly active antiretroviral therapy: collaborative analysis of prospective studies. Lancet 2002; 360 (9327): 119-29
23. Herschel B. Planned interruptions of anti-HIV treatment. Lancet Infect Dis 2001; 1 (1): 53-9
24. Moss RB, Jensen FC, Carlo DJ, et al. The strategy of immunologic control of HIV-1 with structured treatment interruptions (STIs). Curr Drug Targets Infect Disord 2001; 1 (1): 11-7
25. Lori F, Foli A, Lisziewicz J. Structured treatment interruptions as a potential alternative therapeutic regimen for HIV-infected patients: a review clinical data and future prospects. J Antimicrob Chemother 2002; 50 (2): 155-60
26. Lisziewicz J, Lori F. Structured treatment interruptions in HIV/AIDS therapy. Microbes Infect 2002; 4 (2): 207-14
27. Deeks SG, Martin JN. Reassessing the goal of antiretroviral therapy in the heavily pre-treated HIV-infected patient. AIDS 2001; 15: 117-119
28. Montaner JSG, Harrigan RP, Janke, N, et al. Multiple drug rescue therapy for HIVinfected individuals with prior virologic failure to multiple regimens. AIDS 2001; 15: 61-9
29. Mellors J, Montaner J. Salvage therapy for HIV-1 infection - the challenge grows. Lancet 2000 Apr 22; 355 (9213): 1435
30. Tramarin A, Campostrini S, Postma MJ, et al. A multicentre study of patient survival, disability, quality of life, and cost of care among patients with AIDS in Northern Italy. Pharmacoeconomics 2004; 22 (1): 43-53
31. Bozzette SA, Joyce G, McCaffrey DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med 2001; 344 (11): 817-31
32. Krentz HB, MC Auld, MJ Gill. The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001. CMAJ 2003; 169 (2): 106-110
33. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362 (9377): 22-9
34. Mocroft A, Phillips AN, Friis-Moller N, et al. Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study. Antivir Ther 2002 7 (1): 21-30
35. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353 (9156): 863-8
36. Mocroft A, Brettle R, Kirk O, et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002; 16 (12): 1663-71
37. PLATO Collaboration. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug class. Lancet 2004; 364: 51-62
38. Palella FJ Jr, Deloria-Knoll M, Chmiel JS, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons at different CD4 cell strata. Ann Intern Med 2003; 138: 620-6
39. Lance HC, Neaton JD. When to start therapy for HIV infection: a swinging pendulum in search of data. Ann Intern Med 2003; 138: 680-1
40. Sendi PP, Bucher HC, Harr T, et al. Cost effectiveness of highly active antire-troviral therapy in HIV-infected patients. Swiss HIV Cohrt Study. AIDS 1999; 13 (9): 1115-22